Key Points
- Insider sale: John Paolini sold 58,424 shares at an average price of $53.71 for proceeds of $3,137,953.04, cutting his stake by 47.1% to 65,623 shares; the transaction was made under a pre‑arranged Rule 10b5‑1 plan.
- Company performance and sentiment: Kiniksa beat Q1 estimates with $0.27 EPS and $214.27M revenue (up 55.5% YoY), and multiple brokerages raised price targets, leaving a consensus rating of "Moderate Buy" and a $60.86 price target.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider John Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Down 1.5%
Shares of NASDAQ:KNSA opened at $56.74 on Wednesday. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 63.04 and a beta of 0.17. Kiniksa Pharmaceuticals International, plc has a 52 week low of $24.85 and a 52 week high of $58.20. The firm has a 50 day moving average of $46.57 and a 200 day moving average of $43.32.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 earnings per share. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.22 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on KNSA. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 29th. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 29th. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a "buy" rating in a report on Tuesday, April 28th. Citigroup lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a "buy" rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong-buy" rating in a report on Monday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $60.86.
View Our Latest Analysis on KNSA
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
A number of large investors have recently made changes to their positions in the stock. Rubric Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company's stock valued at $155,320,000 after buying an additional 90,194 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company's stock valued at $128,409,000 after buying an additional 49,802 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company's stock valued at $41,481,000 after buying an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after buying an additional 67,452 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
